Publications by authors named "B Sanchez-Gonzalez"
Article Synopsis
- Aggressive large B-cell lymphomas (LBCL) have diverse biological traits; detecting MYC rearrangements (MYCr) is crucial for understanding their prognosis.
- Current recommendations urge performing cytogenetic tests on all aggressive LBCL cases to identify MYCr, but due to its low occurrence, affordable screening options are necessary.
- Researchers developed a scoring system and algorithm based on immunohistochemical profiles of CD10, LMO2, and MYC to effectively screen for MYCr, achieving high sensitivity and predictive values in both training and validation series.
Article Synopsis
- Avatrombopag is a newly approved treatment for immune thrombocytopenia (ITP), with limited real-world effectiveness and safety data available.
- A study by the Spanish ITP Group involving 268 patients showed that 90.1% of those with low platelet counts improved significantly after starting the drug, with many achieving stable platelet levels.
- The treatment allowed most patients to reduce or stop corticosteroid use, and only a small percentage experienced thrombocytosis or thromboembolic events, indicating its potential as an effective management option for ITP.
Eltrombopag (ELT) is a thrombopoietin-receptor agonist that stimulates platelet (PLT) production in patients with primary immune thrombocytopenia (ITP). One potential mechanism of ELT is modulating the inflammatory response by increasing PLTs binding to leucocytes. This study examined the effect of ELT on leucocyte-PLTs complexes in 38 ITP patients.
View Article and Find Full Text PDFBackground: is a relevant gene involved in B-cell ontogeny and a survival predictor of aggressive large B-cell lymphomas (aLBCL). Most studies assessing mRNA expression have relied on microarray platforms or qRT-PCR methods, overlooking tissue morphology. In this study, we evaluate RNA expression by chromogenic in situ hybridization (CISH) in normal tissue and in a series of 82 aLBCL.
View Article and Find Full Text PDFIntroduction: Immune thrombocytopenia (ITP) is a potentially severe manifestation of systemic lupus erythematosus (SLE) reported in 7-40% of SLE patients. ITP has been associated with a higher risk of organ damage and mortality.
Objectives: To describe which factors are associated with the presence of ITP in SLE patients.